Following a press conference held yesterday with The Honourable Laurie Hawn,
Member of Parliament for Edmonton Centre, Ceapro Inc. (TSX VENTURE:CZO)
("Ceapro" or the Company") is pleased to announce that it has signed a Letter of
Intent with AAFC to collaborate in the commercial development of a unique
variety of oats developed by AAFC. This new variety of oats will enable Ceapro
to extract larger quantities of its flagship product, avenanthramides, which are
bio-active compounds exclusively found in oats in very small quantities.


This Letter of Intent follows an earlier announcement in May 2012 of a
sole-licensing agreement signed between Ceapro and AAFC for the exclusive use by
Ceapro of an innovative AAFC-patented malting technology that dramatically
increase the concentration of avenanthramides in oats. 


Avenanthramides are included in well known brands of cosmetic and personal care
formulations. They are the active ingredients responsible for the observed
anti-itching and anti-irritating beneficial effects for the skin. 


Ceapro scientists were the first to identify the link between the traditional
symptomatic relief from oatmeal and the clinical activity resulting from the
demonstrated anti-allergic and anti-inflammatory properties of avenanthramides. 


Ceapro is the Company that has developed a unique, proprietary expertise in
extracting and purifying these compounds and is the only commercial manufacturer
worldwide. However, the small quantity of available quality feedstock have only
allowed Ceapro to extract small volumes of avenanthramides which has so far
limited the markets to cosmetic and personal care applications in dermatology.
These two agreements signed with AAFC will change this situation.


"Not only have we licensed a methodology to increase the concentrations of
avenanthramides in oats, we now have access to a unique and new variety of oat
that should significantly improve our manufacturing productivity. Given our
stated objective to penetrate large markets like functional food, nutraceuticals
and potentially pharmaceuticals in this new era of "botanical drugs", it was
imperative to be in a position to produce larger quantities and higher
concentrations of avenanthramides to enable us to meet our objective "said
Gilles Gagnon, President and CEO. "We are very pleased with this partnership
with our Canadian Government who is allowing us to transition research on
avenanthramides to promising commercial applications" he added. 


"We are very excited that AAFC has again recognized Ceapro as the worldwide
expert with the unique ability to rapidly develop and commercialize this new oat
variety that not only will be a benefit to Canadian farmers, but also provide
potential health care benefits for Canadians. We expect to make it a big
Canadian success story" said David Fielder, Chief Scientific Officer.


About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business
activities relate to the development and commercialization of active ingredients
for personal care and cosmetic industries using proprietary technology and
natural, renewable resources. The commercial line of natural active ingredients
include beta glucan, avenanthamides (colloidal oat extract), oat powder, oat
oil, oat peptides, and lupin peptides.


To learn more about Ceapro, visit www.ceapro.com. 

FOR FURTHER INFORMATION PLEASE CONTACT: 
Branko Jankovic
Chief Financial Officer
Ceapro Inc.
780.917.8376 (Edmonton)
bjankovic@ceapro.com
www.ceapro.com
Ceapro (TSXV:CZO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Ceapro.
Ceapro (TSXV:CZO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Ceapro.